KHK7791

DRUG7 trials

Sponsors

Kyowa Kirin Co., Ltd.

Conditions

Hyperphosphatemia

Phase 2

A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD

CompletedNCT03831607

Kyowa Kirin Co., Ltd.Hyperphosphatemia

Start: 2018-12-27End: 2019-11-26Updated: 2024-03-07

Dose-finding Study of KHK7791 in Hyperphosphatemia Patients

CompletedNCT03864458

Kyowa Kirin Co., Ltd.Hyperphosphatemia

Start: 2019-04-15End: 2019-12-31Updated: 2024-03-07

Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients

CompletedNCT03864445

Kyowa Kirin Co., Ltd.Hyperphosphatemia

Start: 2019-04-29End: 2019-12-03Updated: 2024-03-07

Phase 3

Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

CompletedNCT04766398

Kyowa Kirin Co., Ltd.Hyperphosphatemia

Start: 2021-03-15End: 2021-09-27Updated: 2021-10-28

Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis

CompletedNCT04766385

Kyowa Kirin Co., Ltd.Hyperphosphatemia

Start: 2021-03-03End: 2021-12-01Updated: 2022-01-11

Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

CompletedNCT04767581

Kyowa Kirin Co., Ltd.Hyperphosphatemia

Start: 2021-03-08End: 2021-08-10Updated: 2021-09-08

Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

CompletedNCT04771780

Kyowa Kirin Co., Ltd.Hyperphosphatemia

Start: 2021-03-15End: 2022-06-27Updated: 2023-08-02

Related Papers

Patient characteristics associated with the need for high doses of tenapanor hydrochloride in dialysis patients with hyperphosphatemia: A pooled analysis of three clinical trials

PLoS ONE2026-08-28

Tenapanor reduces phosphate binder pill burden among hemodialysis patients in a post hoc phase 3 analysis

Scientific Reports2026-07-01

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia.

2023-11-048 citations

Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial

Clinical and Experimental Nephrology2023-11-019 citations